ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.724,55
0,36%
Brent Oil
81,295
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. USOTC
  6. Sigyn Therapeutics Inc (QB) (SIGY)

  7. Sigyn Therapeutics Inc (QB) (SIGY) Notícias

SIGY

Sigyn Therapeutics (QB) (SIGY)

Sigyn Therapeutics Inc (QB)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:USOTC:SIGY
DataHoraFonteTítuloCódigoCompanhia
31/01/202418:20Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SIGYSigyn Therapeutics Inc (QB)
14/08/202316:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]USOTC:SIGYSigyn Therapeutics Inc (QB)
08/06/202315:38Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SIGYSigyn Therapeutics Inc (QB)
17/05/202308:15InvestorsHub NewsWireSigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep™ Trademark ApplicationUSOTC:SIGYSigyn Therapeutics Inc (QB)
15/05/202318:35Edgar (US Regulatory)Quarterly Report (10-q)USOTC:SIGYSigyn Therapeutics Inc (QB)
10/05/202318:27Edgar (US Regulatory)Securities Registration Statement (s-1/a)USOTC:SIGYSigyn Therapeutics Inc (QB)
31/03/202311:06InvestorsHub NewsWireSigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-KUSOTC:SIGYSigyn Therapeutics Inc (QB)
31/03/202307:19Edgar (US Regulatory)Annual Report (10-k)USOTC:SIGYSigyn Therapeutics Inc (QB)
14/09/202213:37InvestorsHub NewsWireSigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease PatientsUSOTC:SIGYSigyn Therapeutics Inc (QB)
03/08/202208:07InvestorsHub NewsWireSigyn Therapeutics to Commence Trading on the OTCQB® Venture ExchangeUSOTC:SIGYSigyn Therapeutics Inc (QB)
23/06/202207:02Edgar (US Regulatory)Securities Registration Statement (s-1)USOTC:SIGYSigyn Therapeutics Inc (QB)
23/05/202206:00TipRanksAnalysts Are Bullish on These Healthcare Stocks: Sigyn Therapeutics (SIGY)USOTC:SIGYSigyn Therapeutics Inc (QB)
04/02/202212:48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SIGYSigyn Therapeutics Inc (QB)
17/12/202110:48InvestorsHub NewsWireSigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or VaccinesUSOTC:SIGYSigyn Therapeutics Inc (QB)
26/10/202111:43Edgar (US Regulatory)Amended Current Report Filing (8-k/a)USOTC:SIGYSigyn Therapeutics Inc (QB)
10/08/202108:18InvestorsHub NewsWireSigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease TargetsUSOTC:SIGYSigyn Therapeutics Inc (QB)
29/07/202111:19InvestorsHub NewsWireSigyn Therapeutics Announces Successful Completion of Animal Pilot StudyUSOTC:SIGYSigyn Therapeutics Inc (QB)
15/07/202109:00InvestorsHub NewsWireSigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood PlasmaUSOTC:SIGYSigyn Therapeutics Inc (QB)
28/06/202110:48InvestorsHub NewsWireThe Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19USOTC:SIGYSigyn Therapeutics Inc (QB)
31/03/202113:49Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)USOTC:SIGYSigyn Therapeutics Inc (QB)
02/11/202010:41InvestorsHub NewsWireSigyn Therapeutics (SIGY) CEO Note: Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory ConditionsUSOTC:SIGYSigyn Therapeutics Inc (QB)
 Apresentando as notícias mais relevantes sobre:USOTC:SIGY

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
CIEL3
CIELO ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
SGPS3
SPRINGS ON
BOV
TPIS3
TRIUNFO PART ON
BOV
TECN3
TECHNOS ON
BOV
RCSL3
RECRUSUL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados